Cancer cachexia is a multifactorial syndrome marked by a severe loss of body weight due primarily to the wasting of skeletal muscle and adipose tissue. This syndrome is often accompanied by systemic ...
MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...
London, UK – 9 th December 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and ...
New research from the University of Oklahoma, published today in Cancer Cell, describes for the first time a "triangle ...
Cancer cachexia, or the wasting syndrome, is a catastrophic condition that causes dramatic and involuntary loss of muscle mass, fat and weight, alongside extreme fatigue, anorexia and anemia in ...
Up to 80 percent of patients with cancer struggle with cachexia, often called wasting syndrome, which is a condition characterized by the inability to gain or maintain body weight. One of the reasons ...
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...
Patients with cancer cachexia and an elevated level of growth differentiation factor 15 (GDF-15) achieved significant increases in body weight with investigational ponsegromab, as well as other ...
Cancer cachexia is a multifactorial syndrome characterized by skeletal muscle loss leading to progressive functional impairment. Despite the ubiquity of cachexia in clinical practice, prevention, ...
In cachexia, liver metabolism is fundamentally reprogrammed. One gene, which normally regulates the liver’s activity throughout the day, ceases to function properly. Using a mouse model, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results